<DOC>
	<DOCNO>NCT00714948</DOCNO>
	<brief_summary>Standard chemotherapy drug generally work kill rapidly divide cell body . Cancers cell rapidly divide cell chemotherapy effective patient . Gemcitabine Cisplatin effective standard drug combination use treat locally advance metastatic urothelial cancer . However , drug shrink tumor patient , generally limited amount time . This led scientist look different way treat cancer . New drug develop treat cancer work differently standard chemotherapy drug . These drug attempt decrease blood supply tumor . By , may limit tumor 's source oxygen nutrient prevent tumor grow . Sorafenib example drug work way . In patient advanced kidney cancer , sorafenib alone show slow progression disease . The purpose study find effect , good and/or bad , combination gemcitabine , cisplatin , sorafenib cancer .</brief_summary>
	<brief_title>Gemcitabine Split-dose Cisplatin ( GC ) Plus Sorafenib Chemotherapy-naïve Patients With Locally Advanced Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must measurable evaluable urothelial cancer . Measurable disease include unresectable metastatic urothelial tract tumor unidimensionally measurable xray , CT/MRI scan physical examination . Evaluable disease restrict patient unresectable primary bladder tumor evaluate response cystoscopy . Pathologic confirmation Department Pathology MSKCC . Karnofsky Performance Status ( KPS ) ≥60 % . Adequate marrow function define granulocyte ≥ 1500 cells/mm 3 , platelet ≥ 100,000 cells/mm 3 , hemoglobin ≥ 8.0 g/dl . Serum creatinine &lt; 2.0 mg/dl 24hour urine sample demonstrate creatinine clearance ≥ 60 ml/min/1.73m2 calculate creatinine clearance ≥ 60 ml/min/1.73m 2 use formula : Jeliffe Equation : estimate creatinine clearance =﻿ 98 x ( 0.8 [ age ( yr ) 20 ] /Serum Creatinine ( mg/dL ) x ( 0.9 Female ) ) Adequate hepatic function define : Total Bilirubin &lt; = 1.5 x ULN AST ALT &lt; = 3.0 x ULN ( &lt; = 5.0 x ULN acceptable liver tumor involvement ) Normal coagulation profile include PT/INR PTT , unless patient receive anticoagulation therapy agent warfarin heparin . Age ≥ 18 year Informed consent Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients encourage continue barrier method contraception two year longer treatment . Prior treatment systemic chemotherapy ( prior intravesical therapy permit ) . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study . Blood Pressure &gt; 150/100 mm Hg . Irradiation within 4 week start protocol . Evidence another active cancer , except nonmelanoma skin carcinoma , insitu carcinoma cervix curatively treat , adenocarcinoma prostate surgically treat posttreatment PSA nondetectable . Significant cardiovascular disease include congestive heart failure ( New York Heart Association Class II high ) active angina pectoris . History myocardial infarction within 6 month . History stroke transient ischemic attack within 6 month . Clinically significant peripheral vascular disease . Evidence bleed diathesis coagulopathy . Presence central nervous system brain metastasis . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 . Minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 . Serious nonhealing wound , ulcer , bone fracture . History persistent gross hematuria . Uncontrolled infection . Hypersensitivity sorafenib , component formulation . Pregnant ( positive pregnancy test ) lactating . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Bladder</keyword>
	<keyword>Urinary</keyword>
	<keyword>SORAFENIB</keyword>
	<keyword>CISPLATIN</keyword>
	<keyword>GEMCITABINE</keyword>
</DOC>